Generic Yutiq Availability
Last updated on May 7, 2025.
Yutiq is a brand name of fluocinolone ophthalmic, approved by the FDA in the following formulation(s):
YUTIQ (fluocinolone acetonide - implant;intravitreal)
-
Manufacturer: ALIMERA SCIENCES INC
Approval date: October 12, 2018
Strength(s): 0.18MG [RLD]
Is there a generic version of Yutiq available?
No. There is currently no therapeutically equivalent version of Yutiq available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yutiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Injector apparatus and method of use
Patent 7,998,108
Issued: August 16, 2011
Inventor(s): Nazzaro; Martin et al.
Assignee(s): pSivida US, Inc. (Watertown, MA)Disclosed herein is an injector device including an inserter element, a head element, an implant and a set of detachable protector elements for secured device handling. The device comprises a stop that controls the penetration depth of the device during injection. The device may comprise a removable catch that prevents the implant from exiting the device due to the advancement of its inserter element. The device may comprise a disengageable block that prevents the implant from exiting the device from its head element. The device may be configured for intraocular drug delivery.
Patent expiration dates:
- January 12, 2028✓✓
- January 12, 2028
-
Injectable sustained release delivery devices
Patent 8,871,241
Issued: October 28, 2014
Inventor(s): Chou Kang-Jye & Guo Hong & Ashton Paul & Shimizu Robert W. & Watson David A.
Assignee(s): pSivida US, Inc.An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027
More about Yutiq (fluocinolone ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic steroids
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.